Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.
Ropidoxuridine is an orally bioavailable pro-drug of IUdR (5-iodo-2'-deoxyuridine). Ropidoxuridine demonstrates strong synergy effects with Alisertib at clinically relevant concentrations[1].
In an orthotopic tumor model, Ropidoxuridine (750 mg/kg/day) and Alisertib (30 mg/kg/day) demonstrate strong synergy effects[1].
[1]. Rampurwala MM, et al. Ropidoxuridine (IPdR) potentiates alisertib (MLN8237) activity in triple-negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-13-16.